FrancophonIA/DGT-Translation_Memory huggingface dataset:
English: ICCVAM (2010), ICCVAM Test Method Evaluation Report.
French: ICCVAM (2010), ICCVAM Test Method Evaluation Report.
Portuguese: ICCVAM (2010). ICCVAM Test Method Evaluation Report.
Finnish: ICCVAM (2010). ICCVAM Test Method Evaluation Report.
Greek: ICCVAM (2010), ICCVAM Test Method Evaluation Report. Nonradioactive local lymph node assay:
Slovak: ICCVAM (2010), ICCVAM Test Method Evaluation Report.
Slovenian: ICCVAM (2010), ICCVAM Test Method Evaluation Report.
Estonian: ICCVAM (2010), ICCVAM Test Method Evaluation Report.
Latvian: ICCVAM (2010), ICCVAM Test Method Evaluation Report.
English: ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
French: ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
Portuguese: ILAR (1996).
Finnish: ILAR (1996). Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
Greek: (1 6) ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
Slovak: ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
Slovenian: ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
Estonian: ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
Latvian: ILAR (1996), Institute of Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals.
English: OECD (2002), Skin Sensitisation: Local Lymph Node Assay.
Spanish: OCDE (2002), Skin Sensitisation: Local Lymph Node Assay.
Italian: OCSE (2002), Skin Sensitisation: Local Lymph Node Assay.
Portuguese: OCDE (2002), Skin Sensitisation: Local Lymph Node Assay.
Finnish: OECD (2002). Skin Sensitisation: Local Lymph Node Assay.
Slovak: OECD (2002), Skin Sensitisation: Local Lymph Node Assay.
Slovenian: OECD (2002), Skin Sensitisation: Local Lymph Node Assay.
Estonian: OECD (2002), Skin Sensitisation: Local Lymph Node Assay.
Latvian: OECD (2002), Skin Sensitisation: Local Lymph Node Assay.
English: OECD (1992), Skin Sensitisation.
Spanish: OCDE (1992), Skin Sensitisation.
Italian: OCSE (1992), Skin Sensitisation.
Portuguese: OCDE (1992). Skin Sensitisation.
Finnish: OECD (1992). Skin Sensitisation.
Slovak: OECD (1992), Skin Sensitisation.
Slovenian: OECD (1992), Skin Sensitisation.
Estonian: OECD (1992), Skin Sensitisation.
Latvian: OECD (1992), Skin Sensitisation.
English: ICCVAM (2009), Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document, Research Triangle Park, NC: National Institute of Environmental Health Sciences.
French: ICCVAM (2009), Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document.
Spanish: ICCVAM (2009), Non-radiactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document, Research Triangle Park, NC: National Institute of Environmental Health Sciences.
Portuguese: ICCVAM (2009). Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document. Research Triangle Park, NC.
Finnish: ICCVAM (2009). Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document.
Slovak: ICCVAM (2009), Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document, Research Triangle Park, NC: National Institute of Environmental Health Sciences.
Slovenian: ICCVAM (2009), Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document, Research Triangle Park, NC: National Institute of Environmental Health Sciences.
Estonian: ICCVAM (2009), Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document, Research Triangle Park, NC: National Institute of Environmental Health Sciences.
Latvian: ICCVAM (2009), Non-radioactive Murine Local Lymph Node Assay: Flow Cytometry Test Method Protocol (LLNA: BrdU-FC) Revised Draft Background Review Document, Research Triangle Park, NC: National Institute of Environmental Health Sciences.
English: The recommended reference chemicals are listed in Table 1. Studies using the proposed reference chemicals should be evaluated in the vehicle with which they are listed in Table 1.
Spanish: En el cuadro 1 se recogen las sustancias de referencia recomendadas, que deben evaluarse en el vehículo con el que figuran en el cuadro 1.
English: = 1,0 mg/ml
Spanish: = 1,0 mg/ml
Portuguese: = 1,0 mg/ml
English: = 3,0 mg/ml
Spanish: = 3,0 mg/ml
Portuguese: = 3,0 mg/ml
English: EC-ECVAM (2007), Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 April 2007.
Spanish: EC-ECVAM (CEVMA de la Comisión Europea) (2007), Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 April 2007.
Portuguese: CE-ECVAM (2007). Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 de abril de 2007.
Finnish: EC-ECVAM (2007). Statement on the validity of in vitro tests for skin irritation.
Slovak: EC-ECVAM (2007), Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 April 2007.
Slovenian: EC-ECVAM (2007), Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 April 2007.
Estonian: EC-ECVAM (2007), Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 April 2007.
Latvian: EC-ECVAM (2007), Statement on the validity of in vitro tests for skin irritation, issued by the ECVAM Scientific Advisory Committee (ESAC26), 27 April 2007.
English: EC-ECVAM (2007), Performance Standards for applying human skin models to in vitro skin irritation testing.
Spanish: EC-ECVAM (CEVMA de la Comisión Europea) (2007), Performance Standards for applying human skin models to in vitro skin irritation testing.
Portuguese: CE-ECVAM (2007). Performance Standards for applying human skin models to in vitro skin irritation testing.
Finnish: EC-ECVAM (2007). Performance Standards for applying human skin models to in vitro skin irritation testing.
Slovak: EC-ECVAM (2007), Performance Standards for applying human skin models to in vitro skin irritation testing.
Slovenian: EC-ECVAM (2007), Performance Standards for applying human skin models to in vitro skin irritation testing.
Estonian: EC-ECVAM (2007), Performance Standards for applying human skin models to in vitro skin irritation testing.
Latvian: EC-ECVAM (2007), Performance Standards for applying human skin models to in vitro skin irritation testing.
English: EC-ECVAM (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 November 2008.
Spanish: EC-ECVAM (CEVMA de la Comisión Europea) (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 November 2008.
Portuguese: CE-ECVAM (2008). Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 de novembro de 2008.
Finnish: EC-ECVAM (2008). Statement on the scientific validity of in vitro tests for skin irritation testing.
Slovak: EC-ECVAM (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 November 2008.
Slovenian: EC-ECVAM (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 November 2008.
Estonian: EC-ECVAM (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 November 2008.
Latvian: EC-ECVAM (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 November 2008.
Maltese: EC-ECVAM (2008), Statement on the scientific validity of in vitro tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29), 5 ta’ Novembru 2008.
English: ET 50 Can be estimated by determination of the exposure time required to reduce cell viability by 50 % upon application of the marker chemical at a specified, fixed concentration, see also IC50.
Spanish: Puede estimarse determinando el tiempo de exposición necesario para reducir la viabilidad celular en un 50 % tras la administración de la sustancia marcadora a una concentración fija determinada; véase también CI50.
Maltese: Negattiv falz Sustanza tat-test identifikata ħażin bħala negattiv jew mhux attiva b’metodu ta’ ttestjar, meta fil-fatt hija pożittiva jew attiva.
English: 2,7 Cat.
Spanish: Sólido
English: 629-19-6 Liquid
Spanish: Disulfuro de di-n-propilo [3]
English: 1310-58-3 Liquid
Spanish: Hidróxido de potasio (solución acuosa al 5 %)
English: 7340-90-1 Liquid
Spanish: 5-(1,1-Dimetiletil)-2-metilbencenotiol
English: 5271-27-2 Solid 3,3 Cat.
French: éthyl-3-phényl-1-pipérazine
Spanish: etil-3-fenil-1-piperazina
English: The sensitivity should be equal or higher (≥) than 80 % (2) (8) (23). However, a further specific restriction applies to the sensitivity of the proposed in vitro method inasmuch as only two in vivo Category 2 chemicals, 1-decanol and di-n-propyl disulphide, may be misclassified as No Category by more than one participating laboratory.
Spanish: La sensibilidad debe ser igual o superior (≥) al 80 % (2) (8) (23).
English: Measurements of cell proliferation are made to ensure that the treated cells have undergone mitosis during the assay and that the treatments are conducted at appropriate levels of cytotoxicity (see Paragraph 29). Cytotoxicity should be determined with and without metabolic activation in cells that require metabolic activation using the relative increase in cell counts (RICC) or relative population doubling (RPD) (see Appendix 2 for formulas) unless cytoB is used.
Spanish: Se mide la proliferación celular para asegurarse de que las células tratadas han efectuado una mitosis durante el ensayo y de que los tratamientos se efectúan a los niveles adecuados de citotoxicidad (véase el punto 29).
English: Theoretical considerations, together with published data (18) indicate that most aneugens and clastogens will be detected by a short term treatment period of 3 to 6 hrs in the presence and absence of S9, followed by removal of the test substance and a growth period of 1,5-2,0 cell cycles (6). Cells are sampled at a time equivalent to about 1,5-2,0 times the normal (i.e. untreated) cell cycle length either after the beginning or at the end of treatment (See Table 1). Sampling or recovery times may be extended if it is known or suspected that the test substance affects the cell cycling time (e.g. when testing nucleoside analogues).
Spanish: Una serie de consideraciones teóricas, junto con datos publicados (18), indica que la mayoría de los anéugenos y clastógenos se detectan con un corto período de tratamiento, de entre 3 y 6 horas en presencia y ausencia de S9, seguido de la eliminación de la sustancia problema y de un período de crecimiento de entre 1,5 y 2,0 ciclos celulares (6).
English: In the extended treatment, options are offered to allow treatment of the cells with the test chemical in the absence or presence of cytoB. These options address situations where there may be concern regarding possible interactions between the test substance and cytoB.
Spanish: Los tiempos de la toma de muestras o los de recuperación pueden ampliarse si se sabe o se sospecha que la sustancia problema afecta a la duración del ciclo celular (por ejemplo, cuando se someten a ensayo análogos de nucleósidos).
Portuguese: No caso desse tratamento prolongado, apresentam-se duas possibilidades de tratamento das células com o produto químico em estudo, na ausência ou na presença de citocalasina B. Essas possibilidades alternativas destinam-se a superar as situações em que se tema a eventual interação da substância em estudo com a citocalasina B.
English: The suggested cell treatment schedules are presented in Table 1. These general treatment schedules may be modified depending on the stability or reactivity of the test substance or the particular growth characteristics of the cells being used.
Spanish: Debido a la posible citotoxicidad de las preparaciones de S9 para las células de mamífero cultivadas, se aplica un tratamiento con exposición prolongada de 1,5-2,0 ciclos celulares normales solamente en ausencia de S9.
English: All treatments should commence and end while the cells are growing exponentially. These schedules are presented in more details in paragraphs 41-47 following. Table 1
Spanish: En el tratamiento prolongado, se ofrecen opciones que permiten el tratamiento de las células con la sustancia problema en ausencia y en presencia de citoB.
English: Cell treatment and harvest times for the MNvit assay Lymphocytes, primary cells and cell lines treated with cytoB + S9
Spanish: Estas opciones se refieren a situaciones en que puede haber preocupación respecto a posibles interacciones entre la sustancia problema y la citoB.
English: Treat for 3-6 hrs in the presence of S9; remove the S9 and treatment medium;
Spanish: Las pautas sugeridas de tratamiento de las células se presentan en el cuadro 1.
English: Option B: Treat for 1,5-2,0 normal cell cycles; remove the test substance;
Spanish: Opción A: Tratar durante 1,5-2,0 ciclos celulares normales en presencia de citoB;
Maltese: Għażla A: Trattament għal 1,5–2,0 ċikli ta’ ċelloli normali fil-preżenza tas-cytoB;
English: However, it might be more appropriate to follow Option A for stimulated lymphocytes where exponential growth may be declining at 96 hrs following stimulation. Also, cultures of cells should not have reached confluence by the final sampling time in Option B.
Spanish: Sin embargo, podría ser más adecuado seguir la opción A en caso de linfocitos estimulados en que el crecimiento exponencial podría declinar a las 96 horas de la estimulación.
Slovenian: Vendar je za stimuliranje limfocitov, pri katerih se lahko eksponentna rast po 96 urah po stimulaciji zmanjšuje, morda primernejša možnost A. Pri možnosti B celične kulture do končnega časa vzorčenja ne smejo postati strjene.
Maltese: Fl-analiżi inizjali, iċ-ċelloli jiġu ttrattati għal 3 sa 6 sigħat bis-sustanza tat-test fin-nuqqas jew fil-preżenza ta’ S9.
English: Primary cells and cell lines should be treated in a similar manner to lymphocytes except that it is not necessary to stimulate them with PHA for 44-48 hrs. Cells other than lymphocytes should be exposed such that at the time of study termination, the cells are still in log-phase growth. Cell lines without cytoB
Spanish: El medio de tratamiento se retira y se sustituye con medio fresco, y las células se recogen cuando han pasado otros 1,5-2,0 ciclos celulares normales.
English: If both initial tests of the short (3-6 hrs) treatment are negative or equivocal, a subsequent, extended exposure treatment (without S9) is used. Two treatment options are available, both of which are equally acceptable:
Spanish: El medio de tratamiento se retira y se sustituye con medio fresco, y las células se recogen al cabo de un tiempo equivalente a 1,5-2,0 ciclos celulares normales.
Maltese: Il-mezz tat-trattament jitneħħa u jiġi sostitwit b'mezz frisk, u ċ-ċelloli jittieħdu wara 1,5–2,0 ċikli taċ-ċelloli normali.
English: ECVAM (2006), Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
Spanish: CEVMA (2006), Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to thein vitro chromosome aberration assay for genotoxicity testing.
Portuguese: ECVAM (2006). Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
Finnish: ECVAM (2006). Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
Slovak: ECVAM (2006), Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
Slovenian: ECVAM (2006), Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
Estonian: ECVAM (2006), Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
Latvian: ECVAM (2006), Statement by the European Centre for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee (ESAC) on the scientific validity of the in vitro micronucleus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing.
English: Apoptosis programmed cell death characterised by a series of steps leading to a disintegration of cells into membrane-bound particles that are then eliminated by phagocytosis or by shedding. Cell proliferation increase in cell number as a result of mitotic cell division.
Spanish: Apoptosis Muerte celular programada, caracterizada por una serie de fases que llevan a la desintegración de las células para formar partículas limitadas por membranas que se eliminan a continuación por fagocitosis o por liberación.
English: Polyploidy numerical chromosome aberrations in cells or organisms involving entire set(s) of chromosomes, as opposed to an individual chromosome or chromosomes (aneuploidy). Proliferation Index (PI) method for cytotoxicity measurement when cytoB is not used (see Appendix 2 for formula).
Spanish: Poliploidía Aberraciones cromosómicas numéricas en células u organismos que afectan a dotaciones completas de cromosomas, en contraste con las aberraciones que afectan solo a cromosomas individuales (aneuploidía).
English: Replication Index (RI) the proportion of cell division cycles completed in a treated culture, relative to the untreated control, during the exposure period and recovery (see Appendix 2 for formula). Test chemical (also referred to as test substance) Any substance or mixture tested using this TM. --------------------------------------------------
French: Indice de prolifération (PI) Méthode de mesure de la cytotoxicité lorsque la cytoB n’est pas utilisée (voir formule à l’appendice 2).
Spanish: Duplicación relativa de la población (DRP, o RPD por su nombre en inglés) Método de medición de la citotoxicidad cuando no se utiliza la citoB (véase la fórmula en el apéndice 2).
English: When cytoB is used, evaluation of cytotoxicity should be based on the Cytokinesis-Block Proliferation Index (CBPI) or Replicative Index (RI) (16) (58). The CBPI indicates the average number of cell cycles per cell during the period of exposure to cytoB, and may be used to calculate cell proliferation.
Spanish: Apéndice 2
English: % Cytostasis = 100 – 100(CBPIT – 1) ÷ (CBPIC – 1) And:
Spanish: Cuando se utiliza citoB, la evaluación de la citotoxicidad debe basarse en el índice de proliferación con bloqueo de la citocinesis (IPBC) o en el índice de replicación (IR) (16) (58).
English: T test chemical treatment culture C vehicle control culture
Spanish: El IPBC indica el número medio de ciclos celulares por célula durante el período de exposición a la citoB, y puede utilizarse para calcular la proliferación celular.
English: Where: CBPI = No. mononucleate cells
Spanish: El IR indica el número de núcleos presentes en los cultivos tratados respecto al de los cultivos de control y puede utilizarse para calcular el porcentaje de citostasis:
English: Cytostasis = 100 – RI RI = No. binucleated cells
Spanish: Así pues, un IPBC de 1 (todas las células son mononucleadas) es equivalente al 100 % de citostasis.
English: ÷ Total number of cells T
Spanish: IR = no
English: Kimber, I. and Basketter, D.A.
French: Kimber, I., et Basketter, D.A.
Portuguese: Kimber, I., Basketter, D.A.
Swedish: Kimber, I. och Basketter, D.A.
Finnish: Kimber, I. ja Basketter, D. A. (1992).
Slovenian: Kimber, I. and Basketter, D.A.
Estonian: Kimber, I. and Basketter, D.A.
Latvian: Kimber, I. and Basketter, D.A.
English: Kimber, I., Dearman, R.J., Scholes, E.W. and Basketter, D.A.
French: Kimber, I., Dearman, R.J., Scholes, E.W. et Basketter, D.A.
Portuguese: Kimber, I., Dearman, R.J., Scholes, E.W., Basketter, D.A.
Swedish: Kimber, I., Dearman, R.J., Scholes, E.W. och Basketter, D.A.
Finnish: Kimber, I., Dearman, R. J., Scholes, E. W. ja Basketter, D. A. (1994). The local lymph node assay: developments and applications. Toxicol.
Slovenian: Kimber, I., Dearman, R.J., Scholes, E.W. and Basketter, D.A.
Estonian: Kimber, I., Dearman, R.J., Scholes, E.W. and Basketter, D.A.
Latvian: Kimber, I., Dearman, R.J., Scholes, E.W. and Basketter, D.A.
English: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E. and Hastings, K.L.
French: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E. et Hastings, K.L.
Portuguese: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E., Hastings, K.L.
Swedish: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E. och Hastings, K.L.
Finnish: Kimber, I., Hilton, J., Dearman, R. J., Gerberick, G. F., Ryan, C. A., Basketter, D. A., Lea, L., House, R. V., Ladies, G. S., Loveless, S. E. ja Hastings, K. L. (1998).
Slovenian: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E. and Hastings, K.L.
Estonian: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E. and Hastings, K.L.
Latvian: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E. and Hastings, K.L.
Maltese: Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E., Hastings, K.L.